The financing will support SamanTree Medical’s research, development and innovation activities, with a particular focus on the further development and commercialisation of its Histolog® Scanner. This advanced technology enables surgeons and pathologists to obtain rapid, real‑time, histology‑like images of excised tissue during surgical procedures.This improve surgical precision, reducing re‑interventions and ultimately enhancing patient outcomes.
The transaction forms part of the EIB’s venture debt programme and is backed by InvestEU, the European Union’s EUR 372+ billion flagship initiative designed to mobilise long‑term investment in innovation, sustainability and strategic technologies across Europe. The financing is structured to strengthen SamanTree Medical’s cash runway while supporting its commercial expansion across European and US markets, reflecting the increasingly important role of venture debt in scaling research‑intensive med‑tech businesses.
Our team advised on complex EIB and InvestEU-backed financings, combining deep expertise in European public financing instruments with a thorough understanding of venture debt structures and innovation‑driven sectors such as life sciences and healthcare. This integrated approach to financing and corporate matters positions us as a trusted adviser on transactions at the intersection of finance, innovation and public policy.
For more information, please contact our team members below.
